Maximizing Potential Through Strategic Business Development Activity
Maximize the value of our drug discovery efforts
- Secreted proteins program
- Antibody target program
-
Opportunistic in-licensing and partnering strategy
- Pursue universe of pre-clinical and clinical compounds to identify promising development candidates for Nuvelo
- e.g.: Alfimeprase
- Complementary to areas of expertise and ongoing development programs
Monetize the value of non-core assets
- Variagenics assets
- e.g. Sequenom agreement
- Cambridge facility decommissioned
- Callida assets
- Company restructured and wholly financed by grants